Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 8/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CDH1 | P12830 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | RARA | P10276 | 1/20 | 0.37 |
| ▸ | RARB | P10826 | 1/20 | 0.37 |
| ▸ | RARG | P13631 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7968545 | 0.90 | PIK3CG (0.57) | PIK3CGKCNH2PIK3CDPIK3R1PIK3CA | |
| SCHEMBL4566386 | 0.89 | PIK3CG (0.75) | PIK3CGKCNH2PIK3CDPIK3R1PIK3CA | |
| SCHEMBL2994121 | 0.89 | PIK3CG (0.75) | PIK3CGKCNH2PIK3CDPIK3R1PIK3CA | |
| SCHEMBL1178682 | 0.86 | NPC1 (0.55) | PIK3CGALDH1A1MAPTHPGDNPC1 | |
| Dimethylamine SCHEMBL1685907 | 0.86 | PIK3CG (0.54) | PIK3CGKCNH2PIK3CDPIK3R1PIK3CA | |
| SCHEMBL1179168 | 0.85 | NPC1 (0.57) | PIK3CGALDH1A1MAPTHPGDNPC1 | |
| SCHEMBL1178249 | 0.83 | PIK3CG (0.51) | PIK3CGKCNH2PIK3CDPIK3R1PIK3CA | |
| SCHEMBL1178858 | 0.83 | PIK3CG (0.57) | PIK3CGNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27831529 | 0.79 | PIK3CG (0.73) | PIK3CGKCNH2PIK3CDPIK3R1PIK3CA | |
| SCHEMBL1178278 | 0.79 | PIK3CG (0.73) | PIK3CGKCNH2PIK3CDPIK3R1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102105466-B | Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2014-10-15 | — | — | CN | claimed |
| CN-102105466-A | Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB | 2011-06-22 | — | — | CN | claimed |
| US-20100317662-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators - 286 | CACCIOLA JOSEPH | 2010-12-16 | — | — | US | claimed |
| EP-2772492-B1 | Use of an isoxazole derivative for the treatment of withdrawal symptom | ASTRAZENECA AB (SE) | 2016-08-17 | — | — | EP | disclosed |
| CN-102105466-B | Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2014-10-15 | — | — | CN | disclosed |
| EP-2772492-A1 | Use of an isoxazole derivative for the treatment of withdrawal symptom | AstraZeneca AB (SE) | 2014-09-03 | — | — | EP | disclosed |
| EP-2303872-B1 | ISOXAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2014-04-16 | — | — | EP | disclosed |
| CN-102105466-A | Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB | 2011-06-22 | — | — | CN | disclosed |
| US-20100324044-A1 | METABOTROPIC GLUTAMATE RECEPTOR ISOXAZOLE LIGANDS AND THEIR USE AS POTENTIATORS | CACCIOLA JOSEPH | 2010-12-23 | — | — | US | disclosed |
| US-20100317662-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators - 286 | CACCIOLA JOSEPH | 2010-12-16 | — | — | US | disclosed |
| US-7790760-B2 | Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286 | ASTRAZENECA AB (SE) | 2010-09-07 | — | — | US | disclosed |
| US-7781434-B2 | Metabotropic glutamate receptor isoxazole ligands and their use as potentiators—286 | ASTRAZENECA AB (SE) | 2010-08-24 | — | — | US | disclosed |
| US-20100022545-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators - 286 | CACCIOLA JOSEPH | 2010-01-28 | — | — | US | disclosed |
| WO-2009148403-A1 | ISOXAZOLE DERIVATIVES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | WO | disclosed |
| US-20090306158-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators 286 | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022545-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators - 286 | GRM1, GRM3, GRIN1 | PIK3CG 2627/4885KCNH2 892/4885PIK3CD 2609/4885 |
| US-20090306158-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators 286 | GRM1, GRM3, GRIN1 | PIK3CG 2539/4885KCNH2 818/4885PIK3CD 2563/4885 |
| US-20100317662-A1 | Metabotropic Glutamate Receptor Isoxazole Ligands and Their Use as Potentiators - 286 | GRM1, GRM3, GRIN1 | PIK3CG 2627/4885KCNH2 892/4885PIK3CD 2609/4885 |
| US-20100324044-A1 | METABOTROPIC GLUTAMATE RECEPTOR ISOXAZOLE LIGANDS AND THEIR USE AS POTENTIATORS | GRM1, GRM3, GRM2 | PIK3CG 2553/4885KCNH2 799/4885PIK3CD 2686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.